

Almirall and the Spanish Pharmacological Society recognise research into diabetes

- The purpose of this award is to promote pharmacology research in Spain
- It is currently the only award in the pharmacology area that recognises a quality project rather than a completed work

Malaga, 6 October 2011.- The Pharmacology Award ceremony took place yesterday. This award is given by Almirall and the Spanish Pharmacological Society (SEF) and aims to promote pharmacological research in Spain. The award, which in 2011 is now in its tenth year, is the only award in the pharmacology field to recognise the quality of an ongoing project and not an already completed piece of work. The event formed part of the 33rd SEF Congress, which was held in Malaga from 3 – 5 October.

This year the award went to the project *“Mechanism inducing vascular damage in diabetes mellitus and ageing: synergism between inflammation and D-glucose”*, by Dr. Carlos Félix Sánchez Ferrer, from the Autonomous University of Madrid. The award of 9,000 euros is intended for the development of the research project during 2011-2012.

The jury of this tenth edition was made up of the doctors Maite Tejerina (President of the Spanish Pharmacological Society and Professor of Pharmacology at the Complutense University of Madrid), Pilar D'Ocon (council member of the Spanish Pharmacological Society and Professor of Pharmacology at the University of Valencia) and Amadeu Gavalda (Head of Integrative Pharmacology at Almirall). According to Dr. Gavalda: *“The tenth year of the Pharmacology Award is clearly a manifestation of its importance in pharmacological research in Spain. The winning project this year will investigate the inductor mechanisms of vascular damage in diabetes, which is one of the most prevalent pathologies in the world”*.

About Almirall

Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing.

Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and other dermatological conditions.

Almirall's products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 12 affiliates.

For further information please visit the website at: www.almirall.com

More information:

Ketchum Pleon
Victorino Ballester/Sonia San Segundo
victorino.ballester@ketchumpleon.com
Tel.: 91 788 32 00